RxDoctor Payments Data

Quang Binh Nguyen, MD

Family Medicine · Santa Ana, CANPI 1982002598

Payments from drug & device makers

$9,115in general payments, 2019–2025

Across 313 payments — averaging $29.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Abbott$1K
  • Novo Nordisk$1K
  • AstraZeneca$927
  • Bayer$427
  • AbbVie$344
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$8,98499%
  • Education$1311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,115 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$172,699
Medicare patients
669
Services billed
1,939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab48$77,429
JardianceEmpagliflozin71$73,150
Evenity (2 Syringes)Romosozumab-Aqqg29$69,850
VascepaIcosapent Ethyl115$55,535
FarxigaDapagliflozin Propanediol65$46,737
VemlidyTenofovir Alafenamide25$43,638
KerendiaFinerenone35$37,353
RestasisCyclosporine51$34,905
LinzessLinaclotide27$30,444
JanuviaSitagliptin Phosphate36$30,001
TrulicityDulaglutide21$28,731
CreonLipase/Protease/Amylase26$28,638
Diclofenac Sodium103$25,821
EliquisApixaban25$25,749
GemtesaVibegron44$20,401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia, Evenity (2 Syringes)$1,556$147,27977 claims
AbbVieRestasis, Linzess, Creon$344$93,986104 claims
Boehringer IngelheimJardiance, Tradjenta$147$91,54496 claims
AstraZenecaFarxiga$927$46,73765 claims
BayerKerendia$427$37,35335 claims
MerckJanuvia$16$30,00136 claims
Lilly USA, LLCTrulicity$220$28,73121 claims
PfizerEliquis$21$25,74925 claims
Sumitomo Pharma America, Inc.Gemtesa$166$20,40144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →